Article Correctness Is Author's Responsibility: Exact sciences licenses targeted digital sequencing; adds leadership in precision oncology

(The Translational Genomics Research Institute) Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences' leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.